Logo

Amgen Presents Results of Lumakras (sotorasib) in P-I/II (CodeBreaK 100) Trial for KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer at AACR 2022

Share this

Amgen Presents Results of Lumakras (sotorasib) in P-I/II (CodeBreaK 100) Trial for KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer at AACR 2022

Shots:

  • The P-I/II (CodeBreaK 100) trial evaluates Lumakras in patients with KRAS G12C-mutated advanced NSCLC
  • In the 2yr. analysis from 174 heavily pre-treated patients, Lumakras showed a long-term clinical benefit & prolonged tumor response with ORR of 40.7%, DCR (83.7%) & m-DoR (12.3mos.), 5 patients achieved CR & 65 patients achieved PR, m-PFS of 6.3mos. & OS (12.5mos.) with 32.5% of patients still alive @2yr. with no new safety signals during long-term follow-up
  • Lumakras is marketed as Lumykras (sotorasib) in the EU, UK & Switzerland. In May 2021, Lumakras was the 1st KRASG12C inhibitor to receive regulatory approval in the US under accelerated approval & has been approved in 39 countries

Ref: PRNewswire | Image: Amgen

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions